Metabolism News and Research

Latest Metabolism News and Research

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Merck announced today results from a new non-inferiority trial of an antiemetic regimen containing fosaprepitant dimeglumine administered as a single intravenous (IV) 150-mg dose in combination with a 5-HT3 antagonist and dexamethasone compared with a three-day regimen of aprepitant with a 5-HT3 antagonist and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving a first cycle of cisplatin-based chemotherapy.

4 Jun 2010

Roche's new dual-PCR target HIV-1 viral load test receives FDA approval

Roche Molecular Diagnostics announced today that the Food and Drug Administration (FDA) approved its new dual-PCR target HIV-1 viral load test to quantify the amount of virus in a patient's blood. The COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test, v2.0 is the first quantitative viral load test to amplify and detect two separate regions of a target genome and offers a fully automated and reliable solution for physicians to make informed treatment decisions for HIV-1 patients undergoing antiretroviral therapy.

4 Jun 2010

Researchers generate the first comprehensive genetic parts list of mouse hypothalamus

A Johns Hopkins and Japanese research team has generated the first comprehensive genetic "parts" list of a mouse hypothalamus, an enigmatic region of the brain — roughly cherry-sized, in humans — that controls hunger, thirst, fatigue, body temperature, wake-sleep cycles and links the central nervous system to control of hormone levels.

4 Jun 2010

Key regulator of fat cell differentiation identified

New research led by UCD Conway Fellow, Professor Johan Ericsson has identified a key regulator of fat cell differentiation that may be a novel target for obesity drugs. The results of the research are published in the current edition of the scientific journal, Proceedings of the National Academy of Sciences (PNAS).

4 Jun 2010

Study provides personalized strategies to boost AIAA compliance in breast cancer patients

Aromatase inhibitor-associated arthralgia (AIAA) is a major side effect in breast cancer survivors, producing joint pain so severe that as many as ten percent of women discontinue their therapy prematurely while undergoing treatment with these lifesaving drugs.

3 Jun 2010

Research may yield new urine test to diagnose autism

Children with autism have a different chemical fingerprint in their urine than non-autistic children, according to new research published tomorrow in the print edition of the Journal of Proteome Research.

3 Jun 2010

Phase III study of Afinitor tablets in patients with advanced pancreatic NET meets primary endpoint

Novartis Pharmaceuticals Corporation announced today that a Phase III study of Afinitor (everolimus) tablets plus best supportive care met its primary endpoint, showing the drug significantly extended progression-free survival, or time without tumor growth, in patients with advanced pancreatic neuroendocrine tumors.

3 Jun 2010

Entelos' T1D PhysioLab platform published in Clinical and Experimental Immunology

Entelos, Inc. has announced a publication in the peer-reviewed journal Clinical and Experimental Immunology describing the Type 1 Diabetes (T1D) PhysioLab® platform, an in silico solution for rapidly streamlining preclinical research through the evaluation of alternative scenarios for therapeutic strategies.

2 Jun 2010

ENMD-2076 demonstrates antitumor activity against murine xenograft models of CRC: Study

EntreMed, Inc., today announced the publication of preclinical results for its clinical-stage Aurora A/angiogenic kinase inhibitor, ENMD-2076, in human colorectal cancer xenograft models. The results of the study, conducted by EntreMed collaborators at the University of Colorado School of Medicine, were published in the June 1, 2010 issue of Clinical Cancer Research (Vol. 16, Issue 11).

2 Jun 2010

Genes influence AIAA side effect in breast cancer survivors

2 Jun 2010

Roche, ATCC partner to research real-time endogenous GPCR function with xCELLigence System

G-coupled protein receptors (GPCRs), also known as 7-transmembrane proteins, constitute the single largest class of therapeutic targets for clinical and investigational drugs. There are ~800 predicted members of this class in the human genome, involved in diverse signaling pathways in a wide array of cells and tissue types. Modulation of GPCR function has proven to have therapeutic benefit in a wide variety of diseases in immunology, neurology, cardiology, and oncology.

2 Jun 2010

Juvenile Diabetes Research Foundation International honors Roche with "Chancellor's Award"

Roche, makers of ACCU-CHEK® blood glucose meters, infusion pumps, lancing devices and data management systems for people with diabetes, received the Juvenile Diabetes Research Foundation International's "Chancellor's Award" during the JDRF Annual Conference in Washington, D.C. The "Chancellor's Award" recognizes and honors longstanding JDRF corporate partners.

From Roche Sequencing and Life Science 2 Jun 2010

Postdoctoral scientists receive NYSCF-Druckenmiller Fellowship award

The New York Stem Cell Foundation (NYSCF) today announced the award of eight new NYSCF-Druckenmiller Fellows. These postdoctoral scientists join 15 accomplished stem cell researchers from leading institutions who have been supported by the program since 2006. NYSCF has awarded 23 fellowships to date.

2 Jun 2010

FDA accepts Orexigen's Contrave NDA for treatment of obesity

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for Contrave® (naltrexone SR/bupropion SR), its investigational drug for the treatment of obesity.

2 Jun 2010

Amgen's Prolia receives FDA approval for treatment of postmenopausal women with osteoporosis

Amgen Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Prolia™ (denosumab) for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. Prolia, the first and only FDA-approved RANK Ligand inhibitor, is an every six month 60 mg subcutaneous injection administered by a health care professional.

2 Jun 2010

Sticky gel composed of MPEG-pDHA may help seal wounds created by surgery: Study

A compound found in sunless tanning spray may help to heal wounds following surgery, according to new results published by plastic surgeons from NewYork-Presbyterian Hospital/Weill Cornell Medical Center in New York City and biomedical engineers at Cornell University in Ithaca, N.Y., where the novel compound was developed.

1 Jun 2010

Commonalities between flies and humans make valuable new model for galactosemia

Galactosemia is a metabolic disease resulting from an inherited defect that prevents the proper metabolism of galactose, a sugar commonly found in dairy products, like milk. Exposure of affected people to galactose, can damage most of their organ systems and can be fatal. The ability to study the disease is limited by a lack of animal models.

1 Jun 2010

Roche launches GS Junior System benchtop DNA sequencing platform for life science research

Roche, announced today the global launch of the GS Junior System, the company's new benchtop next-generation DNA sequencing platform for life science research. The GS Junior System, developed by 454 Life Sciences, a Roche company, provides an integrated sequencing and bioinformatics solution, all in a size that is no bigger than a typical desktop laser printer.

From Roche Sequencing and Life Science 28 May 2010

Low frequency ultrasound can heal and regenerate body tissues

When we think of ultrasound, it's usually imaging the inside of the body that springs to mind. However, while ultrasound imaging typically requires frequencies that are 50 to 2500 times higher than those human ear can detect, recent increasing evidence indicates that ultrasound at lower frequency can also be used to help certain body tissues to heal and regenerate. Now research that appears in Open Access Journal of Tissue Engineering published by SAGE-Hindawi suggests that ultrasound could also help tissue grafts to survive and thrive following surgery.

28 May 2010

FDA grants Premarket Approval for Roche Diagnostics' Elecsys Antibody to hepatitis C virus assay

Roche Diagnostics announced today that the U.S. Food and Drug Administration (FDA) granted Premarket Approval for its Elecsys Antibody to hepatitis C virus (anti-HCV) assay. The Elecsys Anti-HCV assay is an in-vitro diagnostic test for the qualitative detection of total antibodies to hepatitis C virus in human serum or plasma.

From Roche Sequencing and Life Science 28 May 2010

Metabolism News and Research

Latest Metabolism News and Research

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Roche's new dual-PCR target HIV-1 viral load test receives FDA approval

Researchers generate the first comprehensive genetic parts list of mouse hypothalamus

Key regulator of fat cell differentiation identified

Study provides personalized strategies to boost AIAA compliance in breast cancer patients

Research may yield new urine test to diagnose autism

Phase III study of Afinitor tablets in patients with advanced pancreatic NET meets primary endpoint

Entelos' T1D PhysioLab platform published in Clinical and Experimental Immunology

ENMD-2076 demonstrates antitumor activity against murine xenograft models of CRC: Study

Genes influence AIAA side effect in breast cancer survivors

Roche, ATCC partner to research real-time endogenous GPCR function with xCELLigence System

Juvenile Diabetes Research Foundation International honors Roche with "Chancellor's Award"

Postdoctoral scientists receive NYSCF-Druckenmiller Fellowship award

FDA accepts Orexigen's Contrave NDA for treatment of obesity

Amgen's Prolia receives FDA approval for treatment of postmenopausal women with osteoporosis

Sticky gel composed of MPEG-pDHA may help seal wounds created by surgery: Study

Commonalities between flies and humans make valuable new model for galactosemia

Roche launches GS Junior System benchtop DNA sequencing platform for life science research

Low frequency ultrasound can heal and regenerate body tissues

FDA grants Premarket Approval for Roche Diagnostics' Elecsys Antibody to hepatitis C virus assay

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves